Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,730.50
  • Today's Change2.00 / 0.12%
  • Shares traded1.06m
  • 1 Year change17.67%
  • Beta0.5565
Data delayed at least 20 minutes, as of May 03 2024 11:41 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy5
Outperform8
Hold9
Underperform3
Sell0

Share price forecast

The 22 analysts offering 12 month price targets for GSK plc have a median target of 1,825.00, with a high estimate of 2,550.00 and a low estimate of 1,200.00. The median estimate represents a 5.58% increase from the last price of 1,728.50.
High47.5%2,550.00
Med5.6%1,825.00
Low-30.6%1,200.00

Dividends

In 2023, GSK plc reported a dividend of 0.58 GBP, which represents a 5.31% decrease from last year. The 19 analysts covering the company expect dividends of 0.61 GBP for the upcoming fiscal year, an increase of 4.83%.
Div growth (TTM)-5.31%
More ▼

Earnings history & estimates

On May 01, 2024, GSK plc reported 1st quarter 2024 earnings of 43.10 per share. This result exceeded the 36.43 consensus of the 9 analysts covering the company and exceeded last year's 1st quarter results by 16.49%.
The next earnings announcement is expected on Jul 31, 2024.
Average growth rate+10.31%
GSK plc reported annual 2023 earnings of 155.10 per share on Jan 31, 2024.
Average growth rate+0.24%
More ▼

Revenue history & estimates

GlaxoSmithKline plc had 1st quarter 2024 revenues of 7.36bn. This bettered the 7.07bn consensus of the 9 analysts covering the company. This was 5.93% above the prior year's 1st quarter results.
Average growth rate+1.76%
GlaxoSmithKline plc had revenues for the full year 2023 of 30.33bn. This was 3.42% above the prior year's results.
Average growth rate-1.10%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.